The deal, which expands Medtronic’s presence in the surgical technology market, involves payments of $480 million for Salient and $105 million for PEAK, not including Medtronic’s previous ownership stake.
Both PEAK and Salient will be under Medtronic’s restorative therapies group, which includes its spinal, neuromodulation, diabetes and surgical technology units.
Related Articles on Medtronic:
Surgical Equipment Business in Better Shape Than Radiology, Cardiology
Medtronic, St. Jude Developing Competing Neurostimulation Systems
Ford, Medtronic Partner on Glucose Monitoring Device for Cars
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
